A cute respiratory tract infections are associated with significant morbidity and mortality in hospitalized patients (1) (2) (3) . In addition to the "classical" viral or bacterial respiratory pathogens such as seasonal influenza A viruses and Streptococcus pneumoniae, numerous infectious agents, including the human metapneumoviruses (hMPV), bocavirus (HBoV), human coronaviruses (HCoV), and avian influenza A/H7N9 virus, have been identified to cause severe human infections in recent years (4) (5) (6) (7) (8) (9) (10) . Mixed infections with two or more respiratory pathogens are common in children, and studies have shown an increased risk of more-severe community-acquired pneumonia in these patients (11, 12) . As most respiratory pathogens produce similar symptoms, rapid and accurate laboratory diagnostic tests are necessary to identify the causative agents, in order for timely administration of suitable treatment and implementation of infection control measures.
The utilization of rapid diagnostic tests for respiratory infections has been associated with significant decrease of antibiotic usage and length of hospital stay (13, 14) . However, testing for all respiratory pathogen targets using singleplex real-time PCRs is laborious and time-consuming. Recently, commercial multiplex real-time PCR assays have been launched for rapid diagnosis of multiple respiratory pathogens. The BioFire FilmArray Respiratory Panel (FA-RP) assay (bioMérieux, Marcy l'Etoile, France) is an FDA-cleared multiplex real-time PCR system for simultaneous detection of 20 respiratory pathogens in a single specimen (15, 16) . However, this system is able to process only one specimen per instrument, severely limiting sample throughput.
More recently, the Luminex NxTAG Respiratory Pathogen Panel (NxTAG-RPP) CE-In Vitro Diagnostics (CE-IVD) version assay (Luminex Molecular Diagnostics, Toronto, Canada) has been launched. This new high-throughput multiplex real-time PCR system is modified from the xTAG Respiratory Viral Panel Fast v2 (RVPv2) assay (17) (18) (19) . The NxTAG-RPP assay includes a single-tube reverse transcription (RT)-PCR and DNA hybridization assay, while the previous RVPv2 assay has a two-tube step for RT-PCR and DNA hybridization. The NxTAG-RPP system included all the viral respiratory targets in the RVPv2 and 3 atypical respiratory bacterial targets (Legionella pneumophila, Chlamydia pneumoniae, and Mycoplasma pneumoniae) (20) .
In this study, we evaluated the diagnostic performance of the new Luminex NxTAG-RPP system. The identification results of the new NxTAG-RPP assay were compared with those of the BioFire FA-RP assay and in-house singleplex real-time PCR assays.
MATERIALS AND METHODS
Ethical approval and study specimens. This study was approved by the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Hospital Cluster (UW14-249). Nasopharyngeal (NP) swab specimens collected from patients with symptomatic respiratory tract infection between 1 January and 31 December 2015 were included in the present study. The NP swabs were suspended in viral transport medium and tested using both the BioFire FA-RP and Luminex NxTAG-RPP. As L. pneumophila and HBoV were not included in the FA-RP, the presence of these two pathogens was detected separately using two in-house singleplex real-time PCR assays. Additionally, three nucleic acid extracts from influenza A/H7N9 viral culture with 500 50% tissue culture infective doses (TCID 50 ) were included in the study to assess the performance of the NxTAG-RPP assay on influenza A/H7N9 virus detection. BioFire FilmArray Respiratory Panel. BioFire FA-RP assay version 1.7 (bioMérieux, Marcy l'Etoile, France) is U.S. FDA-cleared and CE-IVD certified. The assay detects nucleic acids of 17 respiratory viruses and 3 bacteria, including adenovirus, HCoV (OC43, NL63, 229E, HKU1), respiratory syncytial virus (RSV), hMPV, influenza A virus (H1/2009, H1 and H3), influenza B virus, parainfluenza viruses (PIV type 1 [PIV1] to PIV4), rhinovirus/enterovirus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae in a multiplex PCR. The extraction, amplification, and detection steps take place in separate chambers of a self-contained, single-use pouch. The procedures were performed according to the manufacturer's instructions.
Luminex NxTAG Respiratory Pathogen Panel. The Luminex NxTAG-RPP assay is a CE-IVD high-throughput multiplex system that can detect nucleic acids of 21 respiratory targets, including all the pathogens detected by the BioFire FA-RP except B. pertussis plus Legionella pneumophila and HBoV in a multiplex PCR.
Nucleic acid extraction. Total nucleic acid extraction was performed on the NucliSENS easyMAG system (bioMérieux, France) according to the manufacturer's instructions. In brief, 10 l of MS2 internal control was first added into 200 l of clinical specimen. The mixture was added to 2 ml external lysis buffer (bioMérieux, France) and was then extracted using the generic protocol with elution volume at 110 l.
Multiplex RT-PCR and hybridization. Thirty-five microliters of extracted total nucleic acid was added to the preplated NxTAG lyophilized bead reagents to resuspend the reaction reagents. RT-PCR was then performed according to the NxTAG-RPP IVD assay product insert instructions. The RT-PCR amplification was performed on a GenAmp 9700 (Life Technologies, CA, USA) with the following cycling parameters: 1 reverse transcription step at 42°C for 20 min; 1 template denaturation step at 95°C for 2 min 30 s; 15 first amplification cycles at 95°C for 20 s, 65°C for 60 s, and 72°C for 10 s; 24 nested amplification cycles at 95°C for 20 s, 58°C for 60 s, and 72°C for 10 s; and a hybridization step at 37°C for 45 min.
Detection and data acquisition. The reaction plate was then transferred to the 37°C preheated Magpix heater plate of the Magpix instrument (Luminex, Austin, TX), and the signal acquisition was performed using the xPONENT and SYNCT software (Luminex, Austin, TX). Each running batch could handle up to 94 clinical specimens plus the positive and negative experiment controls. The total turnaround time was around 5 h.
Real-time PCR for HBoV and L. pneumophila. Individual singleplex real-time PCRs for HBoV and Legionella pneumophila were performed on the 284 nucleic acid extracts. Each 20-l reaction mixture consisted of 1ϫ Premix Ex Taq Probe Mix (TaKaRa Bio Inc., Dalian, China) 0.5 M primers, 0.25 M probe, and 5 l nucleic acid extract (Table 1) . Real-time PCRs were conducted at 95°C for 30 s, followed by 50 cycles at 95°C for 10 s and at 55°C for 30 s in the Roche LightCycler 96 real-time PCR system (Roche Diagnostics, Mannheim, Germany). Each batch of run included one synthetic template control and one no-template control for each target.
Data analysis. The FA-RP and in-house real-time PCR were considered the reference standard method in this study. For adenovirus, HCoV, RSV, hMPV, influenza A viruses, influenza B viruses, PIV, rhinovirus/ enterovirus, C. pneumoniae, and M. pneumoniae, direct comparisons were made between the NxTAG-RPP and FA-RP assays. For L. pneumophila and HBoV, the NxTAG-RPP results were compared with the in-house real-time PCR results.
Statistical analysis. Diagnostic sensitivity and specificity of the assays were calculated using MedCalc version 14.0 (MedCalc Software, Ostend, Belgium). Agreement between the FA-RP and NxTAG-RPP systems was determined by Kappa statistics with SPSS Statistics software version 22.0 (IBM Corp., NY, USA). McNemar's test was used to determine if there was any significant diagnostic performance difference between the two assays using MedCalc version 14.0.
RESULTS
In this study, 284 NP swabs collected from 277 patients with symptomatic respiratory tract infection were tested using the NxTAG-RPP and the reference methods with FA-RP and inhouse real-time PCR for L. pneumophila and HBoV. Among the specimens, at least one respiratory pathogen was found in 254 specimens (Table 2) .
Diagnostic performance of NxTAG-RPP. The overall diagnostic sensitivity and specificity of the NxTAG-RPP were 98.9% (95% confidence interval [CI], 97.2 to 99.7) and 99.0 (95% CI, 98.6 to 99.2), respectively ( Table 2 ). The system demonstrated 100% sensitivity for adenovirus, HCoV-229E, HCoV-NL63, influenza A virus, A/H1pdm09 virus, A/H3 virus, influenza B virus, Agreement between NxTAG-RPP and FilmArray RP. Between the NxTAG-RPP and FA-RP, 18 respiratory pathogen targets were measured in both assays. High agreement between the two assays was observed in 98.8% of positive targets (318/322; kappa ϭ 0.92; 95% CI, 0.90 to 0.94) ( Table 3) . Eleven targets (adenovirus, HCoV-NL63, enterovirus/rhinovirus, influenza virus A, A/H1pdm09, and A/H3, influenza virus B, PIV1, RSV, C. pneumoniae, and M. pneumoniae) showed high agreement between the two assays (kappa ϭ 0.81 to 1.00). The other 7 targets (HCoV-229E, HCoV-HKU1, HCoV-OC43, hMPV, PIV2, PIV3, and PIV4) were demonstrated to have substantial agreement (kappa ϭ 0.61 to 0.80), while significant differences were observed in the diagnostic performance on hMPV (P ϭ 0.001) and PIV3 (P ϭ 0.031) using McNemar's test. Among the 50 specimens with multiple pathogens, 42 (73.7%) showed complete concordance between the two assays. Discordant results were observed in 15 (30.0%) polymicrobial specimens ( Table 4) .
Performance of NxTAG-RPP on HBoV detection. For HBoV detection, the NxTAG-RPP demonstrated high agreement with the in-house HBoV real-time PCR (kappa ϭ 0.95; 95% CI, 0.89 to 1.00). The NxTAG-RPP demonstrated 100% sensitivity and 98.8% specificity in comparison to the reference standard method ( Table 2) .
Detection of influenza virus A/H7N9 culture by NxTAG-RPP. For the 3 avian influenza A/H7N9 viral culture nucleic acid extracts, all of them were detected by the NxTAG-RPP influenza A matrix gene target. All the hemagglutinin subtyping gene targets (H1, H1pdm09, H3) included in the panel were negative for the 3 H7N9 samples.
DISCUSSION
Our study showed that polymicrobial respiratory infections were common, with Ͼ20% of positive cases being infected with two or more pathogens among symptomatic patients in Hong Kong. Therefore, the use of a broad-spectrum multiplexed diagnostic approach could be beneficial due to its requirement for a smaller amount of sample and a shorter turnaround time in comparison to the singleplex approach (21) .
In this study, we evaluated the clinical performance of the new Luminex NxTAG-RPP multiplex PCR assay through the testing of 284 clinical respiratory specimens. In comparison to the reference standard method, the NxTAG-RPP assay demonstrated Ͼ93% sensitivity for most of the respiratory pathogen targets except HCoV-HKU1 and HCoV-OC43. The lower observed sensitivity for CoV HKU-1 and CoV OC43 may be due to the low positive sample number for this target and the fact that NxTAG-RPP detected two of the three positives. This performance represented a significant improvement from the previous Luminex xTAG RVPv2 assay (15, 16, 22) . However, the assay was found to be oversensitive, with false-positive results noted in 12 of 20 targets (60.0%) (adenovirus, HCoV-229E, HCoV-OC43, HCoV-NL63, enterovirus/rhinovirus, influenza A/H3, hMPV, PIV2, PIV3, PIV4, RSV, and HBoV). For hMPV, the positive predictive value (PPV) was Ͻ50% due to the high number of false-positive results (11 false-positive cases). This result was quite different from what was reported in another recently published study (20) . The previous study demonstrated 100% sensitivity and specificity for PIV2, RSV, and hMPV detection. The significantly high false-positive rate of hMPV in our study may be due to nonspecific primer binding and the different specimen handling procedures. To minimize nonspecific reactions, the setup for sample addition and the lyophilized bead reagent strips should be kept cool (cooled cold block or on ice) as suggested by the manufacturer. Based on this data set, adjusting the cutoff value for certain targets may be of value. The prevalence of different viral genotypes in different geographical regions could be a factor contributing to the observed differences among different studies. Due to the limited data about the new NxTAG RPP system, further studies would be necessary to elucidate the reason for the differences. Other than human respiratory pathogens, the increasing reports of human infections caused by avian influenza virus A/H7N9 in China led to a need for close surveillance on H7N9 virus in respiratory specimens from patients with a history of traveling to China (23, 24) . We demonstrated that the NxTAG-RPP influenza A matrix gene target could detect the avian H7N9 virus, whereas the hemagglutinin subtyping targets remained negative.
We further compared the performance of the NxTAG-RPP with the FDA-cleared BioFire FA-RP. The kappa index of 0.92 indicated almost perfect agreement between their diagnostic performances, with no significant difference observed (25) . For patients with multiple pathogens, both the NxTAG-RPP and FA-RP assays demonstrated excellent sensitivity in detecting up to 4 pathogens in a single specimen. The relatively high false-positive Furthermore, NxTAG-RPP was the only multiplex assay in this study that could detect HBoV. Since HBoV is one of the causative agents of pediatric acute respiratory tract infections (6, 26, 27) , the NxTAG-RPP has an additional advantage among the pediatric population. Our study also supported that the NxTAG-RPP has good diagnostic performance for HBoV detection in patients infected with multiple respiratory pathogens.
In addition to diagnostic performance, sample throughput and ease of use are also important factors to consider when choosing a multiplex PCR. The Luminex Magpix is designed for highthroughput screening and is capable of handling a maximum of 96 NxTAG-RPP reactions per batch of run within 5 to 7 h (20) . In contrast, the BioFire FilmArray system has limited capacity since each instrument can test only one sample in 1 h. Therefore, the Luminex system may be more suited for large-scaled laboratories where routine screening of respiratory pathogens is performed on a large number of clinical specimens, while the use of FilmArray system may be useful in laboratories that have limited equipment for nucleic acid extraction or PCR amplification and a low number of specimens. However, the limited capacity of the FA-RP assay may mean that installation of more than one instrument is required to meet their daily test request needs, which has significant cost implications. Comparing the ease of use, both the NxTAG-RPP and FA-RP assays are simple. The hands-on time per run for the NxTAG-RPP is around 30 min, which is a bit longer than for the FA-RP. This is due to the separate nucleic acid extraction step and the need of daily maintenance of the Magpix machine.
In conclusion, the NxTAG-RPP has very good diagnostic performance on multiplex respiratory pathogen detection and is comparable to the FDA-cleared BioFire FA-RP assay. The support of high-throughput sample handling makes this assay a potentially useful tool in major laboratories processing a high number of clinical respiratory specimens for routine screening of multiple respiratory pathogens.
